巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Aditxt

ADTX
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Aditxt - 延遲價格・最後更新於 26/01 12:15
最高位
0.450
最低位
0.420
開市價
--
前收市價
0.456
成交量(千)
48.13
成交額(百萬)
0.19
買入
--
賣出
--
每手股數
--
市值(百萬)
19.36
市盈率
--
息率
--
差價
--
52週高低
5.590 - 0.360
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Aditxt
證券代碼
ADTX.US
所屬板塊
Biotechnology
公司業務
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
發行量
14688248
董事局成員
    公司總部
    737 Nnorth Fifth Street, Suite 200
    公司網址
    https://www.aditxt.com
    公司電話
    +1 909 488-0844
    暫無內容

    關於

    Aditxt(ADTX.US)所屬的行業板塊為Biotechnology。
    Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
    詳細公司背景可參考: https://www.aditxt.com